Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.88 |
| ▸ | PGR | P06401 | 5/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.88 |
| ▸ | USP2 | O75604 | 3/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.88 |
| ▸ | MLNR | O43193 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.88 |
| ▸ | PPARG | P37231 | 1/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596943 | 1.00 | NR3C1 (0.88) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL11580239 | 1.00 | NR3C1 (0.88) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL11580246 | 1.00 | NR3C1 (0.88) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL11580241 | 0.96 | NR3C1 (0.87) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL11580237 | 0.96 | NR3C1 (0.87) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL81051 | 0.96 | NR3C1 (0.87) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL11582001 | 0.95 | NR3C1 (0.84) | NR3C1PGRCYP3A4USP2LMNA | |
| SCHEMBL11582000 | 0.94 | NR3C1 (0.83) | NR3C1PGRCYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL445257 | 0.94 | PGR (1.00) | NR3C1PGRCYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL3997 | 0.94 | PGR (1.00) | NR3C1PGRCYP3A4USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154586-A | Powder aerosol composition for inhalation, powder aerosol for inhalation, preparation method of powder aerosol for inhalation and powder aerosol for inhalation | 上海臣邦医药科技股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20250002591-A1 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHERMATOSUS PATIENTS | ASTRAZENECA AB (SE) | 2025-01-02 | — | — | US | claimed |
| CN-119095616-A | Combination therapy comprising anti-IL-23 antibodies and corticosteroids for the treatment of psoriasis | 太阳医药工业有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-4412641-A2 | TREATMENT OF LUPUS | Astrazeneca AB (SE) | 2024-08-14 | — | — | EP | claimed |
| EP-4377349-A1 | TREATMENT OF LUPUS | Astrazeneca AB (SE) | 2024-06-05 | — | — | EP | claimed |
| CN-118076379-A | Treatment of lupus | 阿斯利康(瑞典)有限公司 | 2024-05-24 | — | — | CN | claimed |
| EP-4337696-A1 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS | Astrazeneca AB (SE) | 2024-03-20 | — | — | EP | claimed |
| CN-117677638-A | Treatment of lupus | 阿斯利康(瑞典)有限公司 | 2024-03-08 | — | — | CN | claimed |
| EP-4326322-A1 | TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS | Astrazeneca AB (SE) | 2024-02-28 | — | — | EP | claimed |
| CN-117538437-A | Method for determining clobetasol butyrate in cosmetics | 上海市食品药品检验研究院 | 2024-02-09 | — | — | CN | claimed |
| EP-1087747-B1 | FOAMING COMPOSITION FOR HAIR CARE | GALDERMA SA (CH) | 2005-11-09 | — | — | EP | claimed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | claimed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | claimed |
| US-20040220155-A1 | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith | PHARMACIA CORPORATION | 2004-11-04 | — | — | US | claimed |
| WO-2004094373-A2 | A METHOD OF PROVIDING A STEROID-SPARING BENEFIT WITH A CYCLOOXYGENASE-2 INHIBITOR AND COMPOSITIONS THEREWITH | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-5171576-A | Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug | ALZA CORPORATION (US) | 1992-12-15 | — | — | US | claimed |
| US-5118509-A | Inducing skin tolerance to a sensitizing drug | ALZA CORPORATION (US) | 1992-06-02 | — | — | US | claimed |
| US-5077054-A | Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug | ALZA CORPORATION (US) | 1991-12-31 | — | — | US | claimed |
| US-5049387-A | Inducing skin tolerance to a sensitizing drug | ALZA CORPORATION (US) | 1991-09-17 | — | — | US | claimed |
| US-5000956-A | Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug | ALZA CORPORATION (US) | 1991-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220155-A1 | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith | CYP21A2, CYP17A1, CYP11B2 | NR3C1 48/4885PGR 670/4885CYP3A4 471/4885 |
| US-20050245497-A1 | Treatment of ophthalmic conditions | MC2R, NR3C2, PTGIR | NR3C1 6/4885PGR 529/4885CYP3A4 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.